TRAW stock icon

Traws Pharma
TRAW

4.65 USD
+0.00
0.00%
Updated Oct 22, 10:34 AM EDT
1 day
0.00%
5 days
-6.25%
1 month
-38.00%
3 months
-58.41%
6 months
-72.29%
Year to date
-76.46%
1 year
-71.92%
5 years
-98.56%
 

About: Traws Pharma Inc is a biopharmaceutical company focused on developing antivirals for influenza, COVID and other respiratory infections and narazaciclib.

Employees: 17

Healthcare Pharmaceutical Preparations
0
Funds holding %
of 6,740 funds
–
Analysts bullish %

Fund manager confidence

Based on 2024 Q2 SEC filings by fund managers ($100M+ AUM)

100% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 4

17% more repeat investments, than reductions

Existing positions increased: 7 | Existing positions reduced: 6

16% more funds holding

Funds holding: 25 [Q1] → 29 (+4) [Q2]

3.15% more ownership

Funds ownership: 8.25% [Q1] → 11.4% (+3.15%) [Q2]

26% less capital invested

Capital invested by funds: $1.75M [Q1] → $1.29M (-$461K) [Q2]

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for TRAW.

See Analyst Rankings

Financial journalist opinion

Neutral
GlobeNewsWire
2 weeks ago
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Investigational agent in development as a one dose treatment or prevention of seasonal and pandemic influenza A dose ranging, Phase 1 study in healthy volunteers demonstrated positive tolerability results and plasma levels in the predicted therapeutic window, enabling selection of Phase 2 dose Preclinical data showed potent inhibition of drug-resistant and bird influenza viruses Phase 2 study expected to begin in H1 2025 Improved therapy is an important need for both seasonal and pandemic flu NEWTOWN, Pa., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases, today announced positive topline Phase 1 safety and pharmacokinetic results for its investigational one-dose influenza (flu) therapy, tivoxavir marboxil (tivoxavir).
Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
Neutral
GlobeNewsWire
3 weeks ago
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Ratutrelvir was well-tolerated for 10 days and achieved consistent plasma levels in the predicted therapeutic window, without the need for co-administration of ritonavir
Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
Neutral
GlobeNewsWire
1 month ago
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Experienced Life Sciences Executive Brings Strategic Expertise to Support Traws' Further Transformation and Growth
Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
Neutral
GlobeNewsWire
1 month ago
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Three proposals, including a reverse stock split, were submitted and approved Traws Board subsequently approved a 1-for-25 reverse stock split Traws' shares expected to begin trading on a split-adjusted basis on September 23, 2024 NEWTOWN, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (Nasdaq: TRAW) (“Traws” or “the Company”), a clinical-stage biopharmaceutical company developing oral small molecule therapies for the treatment of respiratory viral diseases and cancer, today announced the results of the Company's 2024 Special Meeting of Stockholders held on September 16, 2024.
Traws Pharma, Inc. Announces Special Shareholders Meeting Results
Neutral
Seeking Alpha
2 months ago
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Traws Pharma, Inc. (NASDAQ:TRAW ) Corporate Update Call August 15, 2024 8:00 AM ET Company Participants Bruce Mackle - LifeSci Advisors, IR Werner Cautreels - CEO Mark Guerin - CFO Conference Call Participants Chong Liu - Ladenburg Thalmann Operator Operator Ladies and gentlemen, welcome to Traws Pharma, Inc. Corporate Update Call. At this time all participants are in a listen-only mode.
Traws Pharma, Inc. (TRAW) Corporate Update Call Transcript
Neutral
GlobeNewsWire
2 months ago
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Merger with Trawsfynydd Therapeutics, Inc (“Trawsfynydd”) and concurrent private placement of $14 million (cash runway to support planned operations through year end), with recently achieved clinical milestones, put Traws on track to achieve key readouts for the clinical pipeline in H2 2024 and beyond
Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
Neutral
GlobeNewsWire
2 months ago
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
NEWTOWN, Pa., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (“Traws” or “Traws Pharma”), a clinical stage biopharmaceutical company developing oral small molecules for respiratory viral diseases and cancer, today announced that following the release of its second quarter financial results, the Company intends to host a conference call and live webcast on Thursday, August 15, at 8:00 AM ET to provide a corporate update.
Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
See News Rankings
Charts implemented using Lightweight Charts™